Francophone - Webagoo.eu

C 17
DE L’ AVANTGARDE AU STENT ACTIF CRE8 DÉPOURVU DE TOUT POLYMÈRE
FROM AVANTGARDE TO THE CRE8 POLYMER-FREE DES
J. DENS, Genk - BEL
Jo Dens, MD, Interventional Cardiologist, St. Jans Hospital, Genk (Belgium), discussed unique features and
benefits of Cre8 DES.
Cre8 unique distinctive features - Abluminal Reservoir Technology, Amphilimus Formulation and Bio
Inducer Surface – make Cre8 the only very effective Polymer-Free DES today available.
The proprietary Abluminal Reservoir Technology (ART) provides a consistent drug loading onto the stent
platform, thus enabling a controlled and directed elution exclusively targeted to the vessel wall.
The innovative AmphilimusTM formulation, that is Sirolimus formulated with an organic acid, is the first
known use of a carrier to enhance drug bioavailability and drug distribution to the entire vessel wall.
The Bio Inducer Surface, a second generation integral pure carbon coating, demonstrates excellent results
in terms of stent endothelialization and struts coverage. The use of the Bio Inducer Surface onto
the Cre8 Polymer-Free DES enables faster DES endothelialisation and reduces device thrombogenicity
risk.
Cre8 represents an innovative solution to polymer-free drug elution from a stent. Effective Drug Eluting
Stent allowing for shorter DAPT duration are needed to further improve the clinical outcome of today’s
PCI procedures, and Cre8 may represent the solution to this need
C 18
RESULTATS DE L’ ETUDE RANDOMISEE NEXT COMPARANT LE CRE8 AU
TAXUS LIBERTE - RESULTS OF THE PROSPECTIVE AND RANDOMIZED
TRIAL COMPARING CRE8 TO TAXUS LIBERTE: THE NEXT STUDY
D. CARRIE Toulouse
Didier Carrié, MD, PhD., Chief of the Interventional Cath-Lab at Hôpital de Rangueil, Toulouse (France)
and principal investigator of the study, will present 6-month clinical data of NEXT trial. This prospective,
international, multicenter and randomized First In Man study compares the new CID reservoir-based polymer-free
Cre8 Drug Eluting Stent (DES) to TaxusTM Liberté®.
While the study was designed to show that the Cre8 DES was equivalent to TAXUSTM Liberté® in
patients with coronary artery disease, the Cre8 proved to be superior at 6 months in terms of late
lumen loss with high statistically significant difference (p